AbCellera Biologics Inc. (NASDAQ: ABCL) Q4 2025 Earnings Call Transcript February 24, 2026 AbCellera Biologics Inc. beats ...

Q4 2025 Earnings Call February 24, 2026 5:00 PM ESTCompany ParticipantsTryn Stimart - Chief Legal Officer, CCO, ...

Thalassemia is a group of anemias that result from inherited defects in the production of the beta chain of hemoglobin. It is stabilized by gamma ...

The research by Turkish scientists who developed the 'invisible keys' technology in drug design offers a critical opportunity ...

Pramorelin, also known in scientific literature as a synthetic ghrelin receptor agonist, has emerged as a notable peptide within the broader landscape of endocrine and metabolic research. Its primary ...

Brings 20+ years of clinical development experience in autoimmune and inflammatory diseases, including OX40/OX40L program leadership Will build and lead Imagene’s clinical organization and drive ...

From antibiotic resistance to emerging viral threats, the global demand for new medicines is intensifying, yet traditional drug discovery pipelines remain slow and expensive. A new scientific review ...

Bristol Myers Squibb today announced that the U.S. Food and Drug Administration (FDA) has accepted a New Drug Application (NDA) for iberdomide combined with standard treatment (daratumumab + ...

Researchers have developed RNA therapeutics, called micelles, that can delivery chemotherapeutic drugs to metastasized tumors in mouse models.

Drug resistance continues to limit the long-term benefit of many targeted therapies and chemotherapies against cancer. While “classical” small-molecule ...

Net Product Revenue of $5.4 Million for Fourth-Quarter 2025, with >200 Enrollment Forms at the End of December Operationally Seamless Phase 2/3 Study of Atumelnant for the Treatment of ACTH-Dependent ...

UT Southwestern Medical Center researchers have identified two lipids that work together with a quintessential protein known ...